HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Phase I study of forphenicinol, a new biological response modifier].

Abstract
Forphenicinol, [L-(4-hydroxymethyl-3-hydroxyphenyl) glycine], a new biological response modifier, is a derivative of forphenicine, an inhibitor of chick intestine alkaline phosphatase, discovered by H. Umezawa from the microbial culture filtrate. In order to find an optimal dose schedule of forphenicinol, the drug was given p.o. at doses ranged from 10, 50, 100, 400 to 800 mg once a day for 7 days to 103 patients (39 malignant and 64 benign). No side effect was observed. Statistical analysis was performed on immunological parameters, including WBC; lymphocyte, T-cell, B-cell, T gamma-cell (each % and count); S.I. of PHA and Con A, NK cell activity and K cell activity before and after administration. The patients were divided into the "low-dose" group given less than 100 mg/day of the drug and the "high-dose" group given more than 400 mg/day. Further, on the basis of values of each parameter before administration, the patients were divided into the "low-before" or the "high-before" group, when the pretreated value of parameters was lower or higher than the median of all cases. In the malignant patients, lymphocyte (% and count), T-cell (% and count) and B-cell (% and count) significantly increased in the "low-dose"-"low-before" group (p less than 0.05), but B-cell (%) and S.I. of PHP and Con A decreased in the "low-dose"-"high-before" group. On the contrary, there was no significant change in both the "low-before" and the "high-before" group, when "high-dose" of the drug was given. In the benign patients T gamma-cell (% and count) and NK cell activity were found to be significantly increased in the "high-dose"-"low-before" group, indicating some difference in response of parameter from cancer patients. An optimal dose of forphenicinol for cancer patients was considered to be in a range of 10-100 mg/day.
AuthorsT Terakado, K Saito, K Tajima, H Miyasato, T Suzuki, S Ikeda
JournalGan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 10 Issue 11 Pg. 2309-17 (Nov 1983) ISSN: 0385-0684 [Print] Japan
PMID6639093 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Adjuvants, Immunologic
  • forphenicinol
  • Glycine
Topics
  • Adjuvants, Immunologic (administration & dosage, therapeutic use)
  • Drug Administration Schedule
  • Drug Evaluation
  • Glycine (administration & dosage, analogs & derivatives, therapeutic use)
  • Humans
  • Skin Neoplasms (drug therapy, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: